The earnings call presented significant positive developments, including strengthened leadership, progress in key clinical trials, and potential market impact of vidofludimus calcium. However, challenges such as increased R&D expenses and net losses were also noted. The sentiment leans slightly positive due to the promising clinical trial results and potential market opportunities.

Company Guidance

During the Q3 2024 earnings call for Immunic, the company provided several key metrics and guidance concerning its financial status and clinical development programs. Immunic ended the quarter with $59.1 million in cash, which is expected to fund operations into Q3 2025. R&D expenses were reported at $21.4 million for the quarter, reflecting an increase from the previous year due to costs associated with clinical trials, offset by savings from deprioritized programs. The net loss for the quarter was approximately $24.4 million or $0.24 per share. Significant clinical milestones were also discussed, including the anticipated top-line data from the Phase II CALLIPER trial in progressive MS expected in April 2025, and the continuation of the Phase III ENSURE trials in relapsing MS, with the first trial completion expected by Q2 2026. The company also highlighted ongoing interest from pharmaceutical companies for potential partnerships, driven by the innovative profile and market potential of their lead asset, vidofludimus calcium.

Strengthened Management and Board

Appointment of Jason Tardio as President and COO and Simona Skerjanec to the Board, enhancing the team's expertise in drug commercialization and development.

Positive Phase III ENSURE Program Interim Analysis

The interim analysis of the Phase III ENSURE program for vidofludimus calcium in relapsing MS showed it is not futile, allowing trials to continue as planned.

Phase II CALLIPER Trial Progress

Ongoing Phase II CALLIPER trial of vidofludimus calcium in progressive MS, with top-line data expected in April 2025.

New Clinical Trial Initiation

Enrollment of the first patient in a Phase II clinical trial of vidofludimus calcium in post-COVID syndrome.

Financial Position

$59.1 million in cash expected to fund operations into the third quarter of 2025.

Potential Market Impact

Vidofludimus calcium is projected to reach peak sales of USD 2 billion to USD 6 billion, transforming the oral disease-modifying therapy market for MS.

---

Immunic (IMUX) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

IMUX Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Feb 20, 2025	2024 (Q4)	-0.24 / -	-0.48	―	―	―
Nov 07, 2024	2024 (Q3)	-0.22 / -0.24	-0.51	52.94% (+0.27)
Aug 08, 2024	2024 (Q2)	-0.23 / -0.21	-0.54	61.11% (+0.33)
May 08, 2024	2024 (Q1)	-0.26 / -0.30	-0.58	48.28% (+0.28)
Feb 22, 2024	2023 (Q4)	-0.51 / -0.48	-1.63	70.55% (+1.15)
Nov 14, 2023	2023 (Q3)	-0.55 / -0.51	-0.69	26.09% (+0.18)
Aug 03, 2023	2023 (Q2)	-0.53 / -0.54	-0.72	25.00% (+0.18)
May 11, 2023	2023 (Q1)	-0.52 / -0.58	-0.74	21.62% (+0.16)
Feb 23, 2023	2022 (Q4)	-0.73 / -1.63	-0.72	-126.39% (-0.91)
Nov 03, 2022	2022 (Q3)	-0.67 / -0.69	-0.76	9.21% (+0.07)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

---

IMUX Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Nov 07, 2024	$1.18	$1.18	0.00%
Aug 08, 2024	$1.17	$1.34	+14.53%
May 08, 2024	$1.38	$1.27	-7.97%
Feb 22, 2024	$1.28	$1.22	-4.69%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

---